Biological assessment for brain tumors in 5-ALA-induced fluorescence-guided surgery

Biological assessment for brain tumors in 5-ALA-induced fluorescence-guided surgery - Fluorescence-guided surgery for brain tumors

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005617

Enrollment

Registered

2011-05-20

Start date

2011-01-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain tumors

Interventions

Oral administration of 5-ALA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the requirements described below are includesd. 1. Patients who are hospitalized in order to undergo surgery. 2. Patients whose preoperative diagnosis is glioma, meningioma or metastatic brain tumor. 3. Patients who provide a written informed consent.

Exclusion criteria

Exclusion criteria: Patients who meet any of the conditions described below are excluded. 1. Patients with hypersensitivity to 5-ALA or porphyrins. 2. In case of known or suspected pregnancy, or women who are breast-feeding. 3.In case of known or suspected acute or chronic types of porphyria. 4. In case of renal insufficiency (serum creatinine is more than 2.0mg/dl) 5. In case of hepatic insufficiency (serum gamma glutamyl transpeptidase >100IU/l, ptotronbin time <60% or total bilirubin >3mg/dl) 6. In case of other conditions considered as undesirable for entry in this clinical trial.

Design outcomes

Primary

Measure	Time frame
Histological findings of surgical specimens and 5-ALA induced fluorescence	—

Countries

Japan

Contacts

Public ContactHideyuki Arita

Osaka University Hospital Department of Neurosurgery

h-arita@nsurg.med.osaka-u.ac.jp06-6879-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026